Pharmaceutical News and Articles

Nicotine, Marijuana Use Underreported by Plastic Surgery Patients

Plastic surgery patients who use marijuana also have elevated nicotine levels, according to a study published in the September issue of Plastic and Reconstructi

Causal Link Seen for High Ferritin, Serum Iron With Lower Risk for RA

Genetic predisposition to high ferritin and serum iron status is associated with a lower risk for developing rheumatoid arthritis (RA), according to a study pub

Urban Noise Exposure May Aid Prediction of Myocardial Infarction

Young patients with myocardial infarction (MI) and fewer traditional risk factors often have greater exposure to urban noise, according to a study presented at

Cannabis and Hallucinogen Use Among Adults Remained at Historic Highs in 2023

Past-year use of cannabis and hallucinogens stayed at historically high levels in 2023 among adults aged 19 to 30 and 35 to 50, according to the latest findings

Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

Novavax, Inc. (Nasdaq NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today announced the Novavax COVID-19 Vaccine, Adjuvan

New Pooled Analysis Published in The Lancet Demonstrated Reduced Risk of Combined CV Death or Worsening Heart Failure with Semaglutide

Today, The Lancet published a new pooled, participant-level analysis of patients with heart failure with mildly reduced ejection fraction or heart failure with

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

PASADENA, Calif. (BUSINESS WIRE) Sep. 2, 2024 Arrowhead Pharmaceuticals, Inc. (NASDAQ ARWR) today announced results from the Phase 3 PALISADE study of investiga

FDA Approves Pavblu (aflibercept-ayyh), a Biosimilar to Eylea

FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

Emergent BioSolutions’ ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication